Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 944

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 944
---
--|:--|:---------------------------------------|:--|----:|:--|:--|:--|:-----|:--|----:|:--|:--|
| Operating lease cost | ​ | ​ | ​                                      | $ |  67 | ​ | ​ | ​ | ​    | $ |  67 | ​ | ​ |
| Variable lease cost  | ​ | ​ | ​                                      | ​ |  59 | ​ | ​ | ​ | ​    | ​ |  63 | ​ | ​ |
| Total lease costs    | ​ | ​ | ​                                      | $ | 126 | ​ | ​ | ​ | ​    | ​ | 130 | ​ | ​ |

Supplemental disclosure of cash flow information related to the lease were as follows (in thousands):

| ​                                          
 ​                                          | ​ 
 ​ | ​ 
 ​ | For the Nine MonthsEnded September 30, 
 2024                                   |   |     |   | ​ | ​ | 2023 |   |     |   | ​ 
 ​ |
|:-------------------------------------------|:--|:--|:---------------------------------------|:--|----:|:--|:--|:--|:-----|:--|----:|:--|:--|
| Operating cash flows from operating leases | ​ | ​ | ​                                      | $ | 148 | ​ | ​ | ​ | ​    | $ | 145 | ​ | ​ |

The weighted-average discount rate and remaining lease term were as follows:

| ​                                     | ​ | ​ | As ofSeptember 30,2024 |   |       |   | ​ | ​ | As ofDecember 31,2023 |   |       |   | ​ |
| Weighted-average discount rate        | ​ | ​ | ​                      | ​ | 9.50% | ​ | ​ | ​ | ​                     | ​ | 9.50% | ​ | ​ |
| Weighted-average remaining lease term | ​ | ​ | ​                      | ​ |  2.92 | ​ | ​ | ​ | ​                     | ​ |  3.67 | ​ | ​ |

F-124

TABLE OF CONTENTS

Tvardi Therapeutics, Inc. Notes to CONDENSED Financial Statements
(Unaudited) As of September 30, 2024, the maturities of the Company’s operating lease liabilities were as follows (in thousands):

| Year Ended